Exhibit 99


- --------------------------------------------------------------------------------
                                                                   Press Release


                                 Contact:  Michael Johns
                                           Vice President, Communications
                                           Gentiva Health Services
                                           3 Huntington Quadrangle, 2S
                                           Melville, NY  11747
                                           (631) 501-7442
                                           michael.johns@gentiva.com

                        Investor Contact:  John J. Collura
                                           Executive Vice President, Chief
                                           Financial Officer and Treasurer
                                           Gentiva Health Services
                                           (631) 501-7437
FOR IMMEDIATE RELEASE


             Gentiva Health Services Announces Agreement to Sell its
                   Specialty Pharmaceutical Services Business


     Melville, N.Y., January 2, 2002 -- Gentiva Health Services (Nasdaq: GTIV),
the nation's leading provider of home health care and specialty pharmaceutical
services, today announced that it has entered into a definitive agreement with
Accredo Health, Inc. (Nasdaq: ACDO) to sell the assets and business of Gentiva's
specialty pharmaceutical services for approximately $415 million in cash and
stock consideration, subject to certain conditions. The board of directors for
each of the companies has approved the proposed transaction. The transaction
remains subject to both companies' shareholder approval and regulatory
approvals. Subject to the satisfaction of these conditions, the transaction is
estimated to close in April 2002.

     The consideration to be paid by Accredo for Gentiva's specialty
pharmaceutical net assets will be 50 percent in Accredo common stock and 50
percent in cash. Gentiva currently intends that substantially all of the
proceeds will be distributed to Gentiva shareholders shortly following the
closing of the transaction. Further information on the transaction will be
provided in shareholder proxies from the companies, which are anticipated to be
delivered to shareholders in the first quarter of 2002.

     "The aligning of Gentiva's specialty pharmaceutical services business with
Accredo creates a specialty pharmaceutical distribution capability with
tremendous future




opportunities," said Edward A. Bleechschmidt, Gentiva's chairman, president and
chief executive officer. "At the same time, this transaction creates enhanced
focus on our core home health business, where we maintain our industry
leadership position as the only true national provider."

     After consummation of the transaction and following the distribution of
proceeds, Gentiva will have no debt and a cash balance of $60 million to $80
million. Revenue from Gentiva's continuing home health operations for 2001 is
expected to be approximately $720 million.

     Gentiva will provide further details regarding this agreement on a
conference call scheduled for tomorrow, January 3, 2002, at 11:00 a.m. Eastern
Standard Time. To participate in the call from the United States or Canada,
phone (888) 276-9995. To participate in the call from outside the United States
or Canada, phone (612) 288-0329.

     Gentiva Health Services (Nasdaq: GTIV), a Fortune 1000 company, is the
nation's leading provider of home health care and specialty pharmaceutical
services. With more than 300 locations in the United States, the company had
approximately $1.5 billion in 2000 net revenues. For more information, visit
Gentiva's Web site, "http://www.gentiva.com".

                                     --end--

     Information contained in this news release, other than historical
information, should be considered forward-looking, and is subject to various
risk factors and uncertainties. For instance, the company's strategies and
operations involve risks of competition, changing market conditions, changes in
laws and regulations affecting its industries and numerous other factors
discussed in this release and in the company's filings with the Securities and
Exchange Commission. Accordingly, actual results may differ materially from
those anticipated in any forward-looking statements.


- --------------------------------------------------------------------------------